Results From Phase III KALOS And LOGOS Trials Published In Lancet Respiratory Medicine Shows AstraZeneca's BREZTRI Aerosphere Demonstrated Significant Phase III Gains In Uncontrolled Asthma Vs. ICS/LABA Standards